Balchem (BCPC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, at 8:30 a.m. EDT, with virtual attendance available.
Shareholders are encouraged to review proxy materials and vote by June 17, 2026, or June 15, 2026, for 401(k) plan shares.
Voting matters and shareholder proposals
Election of two directors: David Fischer and Daniel Knutson, both recommended by the board.
Ratification of RSM US LLP as independent registered public accounting firm for fiscal year 2026.
Advisory vote on executive compensation for Named Executive Officers.
Proxies may vote on other business as may properly come before the meeting.
Board of directors and corporate governance
Board recommends all director nominees and proposals presented for shareholder approval.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Balchem
- Record Q1 sales, earnings, and cash flow with growth across all segments and improved margins.BCPC
Q1 20261 May 2026 - Strong 2025 results, board elections, auditor ratification, and performance-based executive pay.BCPC
Proxy filing27 Apr 2026 - Record sales, earnings, and cash flow growth, with increased dividends and strong global expansion.BCPC
Q4 202520 Feb 2026 - Record Q2 earnings and margin gains led by Human Nutrition & Health and Specialty Products.BCPC
Q2 20242 Feb 2026 - Q3 2024 net earnings rose 16.4% on 4.3% higher sales, led by Human Nutrition & Health.BCPC
Q3 202418 Jan 2026 - Record Q1 sales, double-digit profit growth, and margin expansion across all segments.BCPC
Q1 202524 Dec 2025 - Record sales, profit, and cash flow growth, with strong innovation and sustainability progress.BCPC
Q4 20249 Dec 2025 - Record financials, sustainability gains, and strong governance drive all Board-backed proposals.BCPC
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and executive pay up for vote at June 2025 meeting.BCPC
Proxy Filing1 Dec 2025